Pyrimethamine
Cigna drug coverage policy for pyrimethamine tablets (Daraprim and generic) outlining medical necessity criteria for treatment and prophylaxis of toxoplasmosis, cystoisosporiasis, and Pneumocystis pneumonia, preferred product requirements, employer/individual plan brand-generic exceptions, and non-covered indications.
Added requirement that medication is prescribed in combination with leucovorin for all indications and relocated brand/generic step-through to preferred product tables.
Changed various prior language about 'failure, contraindication, or intolerance' to 'patient has tried at least one other therapy' with examples moved to Notes.
Added requirement that certain indications must be prescribed in combination with systemic dapsone OR atovaquone (or systemic clindamycin/atovaquone where specified).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.